|1.||LeBlanc, Michael H: 3 articles (12/2006 - 11/2002)|
|2.||Feng, Yangzheng: 3 articles (12/2006 - 11/2002)|
|3.||Guo, Jun: 2 articles (03/2010 - 12/2009)|
|4.||Ignatius, Myron S: 1 article (06/2013)|
|5.||Poss, Kenneth D: 1 article (06/2013)|
|6.||Pugach, Emily K: 1 article (06/2013)|
|7.||Chen, Eleanor Y: 1 article (06/2013)|
|8.||Zon, Leonard I: 1 article (06/2013)|
|9.||Wills, Airon A: 1 article (06/2013)|
|10.||Hettmer, Simone: 1 article (06/2013)|
|1.||Brain Injuries (Brain Injury)
12/03/2006 - "The results are consistent with the hypothesis that ceramide is involved in TPCK's neuroprotective effects in hypoxic-ischemic brain injury in the newborn rat."
01/01/2003 - "Pretreatment with TPCK reduces brain injury. "
03/03/2000 - "We wished to see if TPCK would reduce brain injury in vivo. "
11/01/2002 - "In this experiment TPCK reduces bcl-2 and caspase-3 concentration in animals who have been shown in our previous studies to be protected by TPCK from hypoxic ischemic brain injury. "
03/03/2000 - "TPCK pretreatment in the newborn rat model of hypoxic-ischemic brain injury reduces DNA fragmentation, nitric oxide production and brain injury."
08/01/2004 - "Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines."
08/01/2004 - "In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. "
06/10/1999 - "Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells."
08/01/2004 - "Together, these features suggest that TPCK could be used as a therapeutic agent for treatment of those tumor cells that are resistant to ligand-induced treatment because of aberrant signaling pathways downstream of the DISC."
01/01/1997 - "More recently, activation of a N-tosyl-L-phenylalanylchloromethyl ketone (TPCK)-sensitive pathway was also suggested to play an important role in apoptosis induction following cancer chemotherapy. "
01/01/1997 - "The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation."
01/01/1979 - "The inhibitory effects of TPCK and TLCK seen in transplanted hepatomas and a colon tumor were not generally seen in normal tissues of the tumor-bearing rats."
06/01/2013 - "Two of these inhibitors, PD98059 and TPCK, had anti-tumor activity as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhabdomyosarcoma that harbored activated mutations in NRAS. "
04/01/2008 - "Thus, TPCK prevented the release of HSV-1 DNA into the nucleus when added to medium 1 hour after infection with tsB7 at 39.5 degrees C followed by a shift down to the permissive temperature. "
01/01/2007 - "Moreover, TPCK treatment prior to V. cholerae infection indicated that proinflammatory cytokine gene expression in Int407 cells is NF-kappaB mediated. "
12/20/1998 - "Neither zVAD.fmk nor TPCK, at the concentrations affecting the apoptotic response, exerted appreciable influence on the virus growth or cellular pathological changes on productive infection, indicating that the pathways leading to the poliovirus-evoked CPE and apoptosis are different."
04/01/2008 - "(i) Exposure of cells at the time of or before infection to l-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK), a serine-cysteine protease inhibitor, prevents the release of viral DNA or expression of viral genes. "
01/01/1987 - "In a normally permissive, fusogenic infection of MHV in L-2 cells, the protease inhibitors TPCK and ZPCK, but not TLCK, were found to inhibit cell fusion. "
12/15/2008 - "Interestingly, treatment of cells with toxic concentrations of TPCK alone was accompanied by full caspase-3 and -7 processing even if it induced necrosis. "
04/17/1998 - "Thus TPCK pretreatment before buprenorphine hydrochloride administration induced apoptosis-independent cell death, presumably necrosis, in NG108-15 cells. "
10/01/1997 - "Serine proteinase inhibitors such as N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) and N alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) were shown to inhibit production of tumour necrosis factor-alpha (TNF-alpha) in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages. "
|1.||Caspase 3 (Caspase-3)
|3.||Tosyllysine Chloromethyl Ketone
|4.||NF-kappa B (NF-kB)
|5.||Protease Inhibitors (Protease Inhibitor)
|7.||Serine Proteases (Serine Protease)
|8.||Serine Proteinase Inhibitors (Serine Protease Inhibitors)
|9.||Etoposide (VP 16)
|2.||Drug Therapy (Chemotherapy)